FRA:MRK - Merck KGaA Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
€85.88 +0.38 (+0.44 %)
(As of 07/20/2018 05:37 AM ET)
Previous Close€85.50
Today's Range€85.14 - €86.24
52-Week Range€76.60 - €115.00
Volume251,574 shs
Average VolumeN/A
Market Capitalization$10.07 billion
P/E RatioN/A
Dividend Yield1.59%
BetaN/A
Merck KGaA logoMERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments. It also provides over-the counter and food supplement products under the Neurobion, Bion3, Seven Seas, Nasivin, Femibion, Dolo-Neurobion, Vivera/Floratil, Sangobion, Vigantoletten, Apaisyl, and Kytta brands. In addition, the company offers life science products and services for use in the discovery, development, and manufacture of biotechnological drugs, as well as in research and application laboratories; and specialty chemicals and functional materials for applications consumer electronics, lighting, coatings, printing technology, paints, plastics, and cosmetics. It has strategic alliances with Pfizer Inc. and Baylor College of Medicine; an agreement with Bristol-Myers Squibb Company for the co-commercialization of Glucophage, an antidiabetic agent in China; a strategic collaboration and license agreement with Intrexon Corporation to develop and commercialize chimeric antigen receptor T-cell cancer therapies; and collaborations with F-star Delta Ltd, as well as a strategic collaboration agreement with Alibaba Health to provide Chinese patients and their families with patient-centric healthcare services. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange FRA
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
SymbolFRA:MRK
CUSIPN/A
Phone+49-6151-720

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares129,240,000
Market Cap$10,070.00

Merck KGaA (FRA:MRK) Frequently Asked Questions

What is Merck KGaA's stock symbol?

Merck KGaA trades on the FRA under the ticker symbol "MRK."

What price target have analysts set for MRK?

23 equities research analysts have issued 12-month price objectives for Merck KGaA's stock. Their forecasts range from €70.00 to €125.00. On average, they anticipate Merck KGaA's stock price to reach €98.77 in the next year. This suggests a possible upside of 15.0% from the stock's current price. View Analyst Ratings for Merck KGaA.

What is the consensus analysts' recommendation for Merck KGaA?

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck KGaA in the last year. There are currently 1 sell rating, 10 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Who are some of Merck KGaA's key competitors?

Who are Merck KGaA's key executives?

Merck KGaA's management team includes the folowing people:
  • Dr. Stefan Oschmann, Chairman of Exec. Board & CEO (Age 61)
  • Dr. Marcus Kuhnert, Chief Financial Officer & Member of Exec. Board (Age 50)
  • Dr. Walter Galinat, Member of Exec. Board (Age 62)
  • Dr. Kai Beckmann, Member of the Exec. Board & CEO of Performance Materials (Age 53)
  • Dr. Udit Batra, Member of Exec. Board & Chief Exec. Officer of Life Sciences (Age 47)

Has Merck KGaA been receiving favorable news coverage?

News stories about MRK stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Merck KGaA earned a news impact score of 0.15 on Accern's scale. They also assigned news articles about the healthcare company an impact score of 46.26 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

What is Merck KGaA's stock price today?

One share of MRK stock can currently be purchased for approximately €85.88.

How big of a company is Merck KGaA?

Merck KGaA has a market capitalization of $10.07 billion.

How can I contact Merck KGaA?

Merck KGaA's mailing address is Frankfurter Strasse 250, DARMSTADT, 64293, Germany. The healthcare company can be reached via phone at +49-6151-720.


MarketBeat Community Rating for Merck KGaA (FRA MRK)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  606 (Vote Outperform)
Underperform Votes:  729 (Vote Underperform)
Total Votes:  1,335
MarketBeat's community ratings are surveys of what our community members think about Merck KGaA and other stocks. Vote "Outperform" if you believe MRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.